Patients with sickle cell disease (SCD) exhibited a decrease in vaso-occlusive crises (VOC) when using l-glutamine or crizanlizumab, while voxelotor helped improve hemoglobin concentrations, according to a study published in Cureus. A systematic review of 12 studies looked into the effects of l-glutamine, crizanlizumab, and voxelotor on patients with SCD regarding their efficacy, response, complications,…
Researchers discovered that the drug voxelotor is safe and efficient for pediatric patients with sickle cell disease (SCD) and published their results in Pediatric Blood & Cancer. SCD forces the body to operate under conditions of deoxygenation, triggering chronic cycles of anemia, hemolysis, and vaso-occlusive crises. These repetitive ischemic injuries can eventually cause end-organ damage…
Researchers demonstrated the effectiveness and safety of 1500 mg as a therapeutic dose of voxelotor in adults and adolescents with sickle cell disease (SCD) and published their results in CPT Pharmacometrics Systems in Pharmacology. The study revealed a persistent effect of the medication for up to 72 weeks of therapy. “Significant relationships between voxelotor concentration…
Voxelotor reduces the occurrence of vaso-occlusive crises (VOCs) and the need for blood transfusions in patients with sickle cell disease (SCD) by inhibiting sickle hemoglobin (HbS) polymerization, according to study findings published in Expert Review of Hematology. Nirmish Shah and colleagues conducted a retrospective analysis of real-world data from the Symphony Health Solutions Integrated Dataverse…
